Methods for evaluating cardiac safety of drug using cardiomyocytes derived from human stem cells

Abstract

A method of assessing drug cardiac safety using human stem cell-derived cardiomyocytes, includes: step (A) of preparing cardiomyocytes by culturing human stem cells to differentiate into cardiomyocytes; step (B) of diluting fibronectin in DPBS (Dulbecco's phosphate buffered saline) at a concentration of 50 μg/ml; step (C) of adding the fibronectin solution, obtained by diluting to the concentration of 50 μg/ml in step (B); step (D) of placing the MEA plate; step (E) of removing the fibronectin solution from specific wells of the MEA plate; step (F) of adding a predetermined medium to the specific wells of the MEA plate; and step (G) of measuring changes in information values about beat rate, spike amplitude and field potential duration depending on whether a drug to be assessed has been added to the wells of the MEA plate.